Highlights of This Issue 5839

SPECIAL FEATURES

CCR Translations 5841
Better Late than Early: FDG-PET Imaging in Metastatic Renal Cell Carcinoma
Michael R. Harrison and Daniel J. George
See article p. 6021

Molecular Pathways 5844
Potential Prostate Cancer Drug Target: Bioactivation of Androstanediol by Conversion to Dihydrotestosterone
James L. Mohler, Mark A. Titus, and Elizabeth M. Wilson

5850
ERK1/2 and p38α/β Signaling in Tumor Cell Quiescence: Opportunities to Control Dormant Residual Disease
Maria Soledad Sosa, Alvaro Avivar-Valderas, Paloma Bragado, Huel-Chi Wen, and Julio A. Aguirre-Ghiso

Review 5858
Thrombotic Microangiopathy with Targeted Cancer Agents
John A. Blake-Haskins, Robert J. Lechleider, and Robert J. Kreitman

HUMAN CANCER BIOLOGY 5867
Resection of Non–Small Cell Lung Cancers Reverses Tumor-Induced Gene Expression Changes in the Peripheral Immune System
Andrew V. Kossenkov, Anil Vachani, Celia Chang, Calen Nichols, Shere Billouin, Wenhwai Horng, William N. Rom, Steven M. Albeda, Michael K. Shore, and Louise C. Shore

ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy
Sarah Minner, Malaika Enodien, Hüseyin Sirma, Andreas M. Luebke, Antje Krohn, Pascale S. Mayer, Ronald Simon, Pierre Tennstedt, Julia Müller, Laura Scholz, Jan C. Brase, Alvin Y. Liu, Hartmut Schlüter, Klaus Pantel, Udo Schumacher, Carsten Bokemeyer, Thomas Steuber, Markus Graeven, Guido Sauter, and Thorsten Schlömm

Characterization of a Cleavage Stimulation Factor, 3′ pre-RNA, Subunit 2, 64 kDa (CSTF2) as a Therapeutic Target for Lung Cancer
Masato Aragaki, Koji Takahashi, Hirohiko Akiyama, Eiji Tsuchiya, Satoshi Kondo, Yusuke Nakamura, and Yataro Daigo

CANCER THERAPY: PRECLINICAL 5901
Combining EGFR and mTOR Blockade for the Treatment of Epithelioid Sarcoma
Xianbiao Xie, Markus P.H. Ghadimi, Eric D. Young, Roman Belousov, Quan-sheng Zhu, Juehui Liu, Gonzalez Lopez, Chiara Colombo, Tingsheng Peng, David Reynoso, Jason L. Hornick, Alexander J. Lazar, and Dina Lev

Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants

Killing of Resistant Cancer Cells with Low Bak by a Combination of an Antimesothelin Immunotoxin and a TRAIL Receptor 2 Agonist Antibody
Xing Du, Laiman Xiang, Crystal Mackall, and Ira Pastan

Dual Kinase Inhibition of EGFR and HER2 Overcomes Resistance to Cetuximab in a Novel In Vivo Model of Acquired Cetuximab Resistance
Kelly M. Quesnelle and Jennifer R. Grandis
5945 | **Targeting Human B-cell Malignancies through Ig Light Chain–Specific Cytotoxic T Lymphocytes**
Jinsheng Weng, Soung-Chul Cha, Satoko Matsueda, Gheath Alatrash, Michael S. Popescu, Qing Yi, Jeffrey J. Molidrem, Michael Wang, Sattva S. Neelapu, and Larry W. Kwak

5953 | **Curcumin Treatment Suppresses IKKβ Kinase Activity of Salivary Cells of Patients with Head and Neck Cancer: A Pilot Study**
Suejung G. Kim, Mysore S. Veena, Saroj K. Basak, Eugene Han, Tracey Tajima, David W. Gjertson, Joshua Starr, Ofer Eidelman, Harvey B. Pollard, Meera Srivastava, Eri S. Srivatsan, and Marlene B. Wang

5962 | **Preclinical Pharmacokinetics and Safety of Sym004: A Synergistic Antibody Mixture Directed against Epidermal Growth Factor Receptor**
Niels Jørgen Østergaard Skartved, Helle Jane Jacobsen, Mikkel Wandahl Pedersen, Pernille Foged Jensen, Jette Wagtberg Sen, Thomas Kjærgaard Jørgensen, Adam Hey, and Michael Kragh

5973 | **ABT-737 Induces Apoptosis in Mantle Cell Lymphoma Cells with a Bcl-2high/ Mcl-1low Profile and Synergizes with Other Antineoplastic Agents**
Cyrille Touzeau, Christelle Dousset, Linda Bodet, Patricia Gomez-Bougie, Stéphanie Bonnaud, Anne Moreau, Philippe Moreau, Catherine Pellat-Decesynyk, Martine Amiot, and Steven Le Gouill

### IMAGING, DIAGNOSIS, PROGNOSIS

5982 | **Automated Volumetric Growth Plate Measurement Using Magnetic Resonance Imaging for Monitoring Skeletal Toxicity in Children Treated on Investigational Drug Trials**
AeRang Kim, Eva Dombi, Jeffrey Solomon, Elizabeth Fox, Frank M. Balis, and Brigitte C. Widemann

5991 | **A Polymorphic −844T/C in Fasl Promoter Predicts Survival and Relapse in Non–Small Cell Lung Cancer**
Wen-Wei Sung, Yao-Chen Wang, Ya-Wen Cheng, Ming-Ching Lee, Kun-Tu Yeh, John Wang, Chih-Yi Chen, and Huei Lee

6000 | **Specific PET Imaging of xC− Transporter Activity Using a 18F-Labeled Glutamate Derivative Reveals a Dominant Pathway in Tumor Metabolism**

6012 | **A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors**

6021 | **Sequential FDG-PET/CT as a Biomarker of Response to Sunitinib in Metastatic Clear Cell Renal Cancer**
Irfan Kayani, Norbert Avril, Jamshed Romani, Simon Chowdhury, Andrea Rockall, Anju Sahdev, Paul Nathan, Peter Wilson, Jonathan Shamsah, Kevin Sharpe, Louise Lim, John Dickson, Peter Ell, Andrew Reynolds, and Thomas Powles

6029 | **Prognostic Impact of ΔTAp73 Isoform Levels and Their Target Genes in Colon Cancer Patients**
Beatriz Soldevilla, Raquel Díaz, Javier Silva, Yolanda Campos-Martin, Conception Muñoz, Vanesa García, José M Garcia, Cristina Peña, Mercedes Herrera, Marta Rodríguez, Irene Gómez, Nagat Mohamed, Margarita M. Marques, Félix Bonilla, and Gemma Domínguez

6037 | **Upregulation of Rac GTPase-Activating Protein 1 Is Significantly Associated with the Early Recurrence of Human Hepatocellular Carcinoma**
Suk Mei Wang, London Lucien P.J. Ooi, and Kam M. Hui

6052 | **Phase I Trial of Cixutumumab Combined with Temsirolimus in Patients with Advanced Cancer**
Aung Naing, Razelle Kurzrock, Angelika Burger, Sachin Gupta, Xiudong Lei, Naifa Busuayi, David Hong, Helen X. Chen, Lawrence A. Doyle, Lance K. Heilbrun, Eric Rohren, Chaan Ng, Chandtip Chandhasin, and Patricia LoRusso
Phase II Trial of Dasatinib in Patients with Metastatic Breast Cancer Using Real-Time Pharmacodynamic Tissue Biomarkers of Src Inhibition to Escalate Dosing

Phase I Study of Oral Gemcitabine Prodrug (LY2334737) Alone and in Combination with Erlotinib in Patients with Advanced Solid Tumors

Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer

Results of a Phase II Trial of Gemcitabine Plus Doxorubicin in Patients with Recurrent Head and Neck Cancers: Serum C18-Ceramide as a Novel Biomarker for Monitoring Response

ABOUT THE COVER

Interleukin-6 (IL-6) has tumor-promoting actions on both malignant and stromal cells in a range of experimental cancer models. In addition, high plasma IL-6 levels are associated with poor prognosis in ovarian cancer, but there is little information as to the source of this IL-6. Ovarian cancer biopsies were stained for IL-6 (left) and automated algorithms used to assess both malignant (right) and stromal (middle) compartments. Expression levels were quantified using an autoscore that combined both the intensity and density of positive pixels. IL-6 staining was seen in both the malignant and nonmalignant cells, but was significantly higher in the malignant cell areas. For further details, see Coward and colleagues on page 6083 of this issue.